Development of a risk scoring system for evaluating the prognosis of patients with Her2-positive breast cancer

Table 3 The specific baseline clinicopathological characteristics of 156 Her2-positive breast cancer samples

	156 Her2-positive breast cancer samples
Age
< 60 years	75
≥ 60 years	81
Stage
I	18
II	92
III	41
IV	3
Unknown	2
Pathologic T stage
T1–2	133
T3–4	23
Pathologic N stage
N0–1	119
N2–3	35
Unknown	2
Pathologic M stage
M0	132
M1	3
Unknown	21
Survival time
≤ 1 year	37
1 year ≤ 3 years	62
3 years ≤ 5 years	31
> 5 years	26

ISSN: 1475-2867